Proactive Investors Interview – Algernon Pharmaceuticals Phase 2 Human Study of Ifenprodil for IPF and Chronic Cough is Now 70% Enrolled
Algernon Pharmaceuticals (CSE: AGN – OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive to share news that the company has reached 70% enrollment for its Phase 2 clinical study of its re-purposed drug Ifenprodil for idiopathic pulmonary fibrosis (IPF) and chronic cough.
Mr. Moreau explains to Proactive how the trial is taking parts at six sites in total with four located in Australia and two in New Zealand. The Phase 2 trial lasts 12 weeks total for patients.
